Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$16.76 +4.7%	$18.74	$13.52 ▼ $35.25	$1.70B	2.22	2.10 million shs	1.77 million shs
DYN Dyne Therapeutics	$12.61 +3.2%	$10.27	$6.36 ▼ $46.81	$1.79B	1.08	2.62 million shs	1.47 million shs
PRME Prime Medicine	$3.61 +12.0%	$3.46	$1.11 ▼ $5.17	$487.83M	2.39	2.53 million shs	2.49 million shs
VCEL Vericel	$36.82 +3.9%	$39.07	$33.09 ▼ $63.00	$1.86B	1.27	499,877 shs	503,226 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.31%	-9.19%	-25.67%	-4.87%	-37.19%
DYN Dyne Therapeutics	+2.09%	-2.24%	+32.68%	+4.53%	-74.02%
PRME Prime Medicine	-0.62%	-11.54%	-28.92%	+149.61%	-26.82%
VCEL Vericel	+0.23%	-0.92%	-6.69%	-13.39%	-26.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.2249 of 5 stars	3.5	0.0	2.6	2.5	0.6
DYN Dyne Therapeutics	3.2403 of 5 stars	4.5	1.0	2.0	4.2	0.0
PRME Prime Medicine	2.8606 of 5 stars	3.4	1.0	1.8	5.0	0.6
VCEL Vericel	2.4939 of 5 stars	3.5	0.0	3.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.07	Buy	$48.45	189.19% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	168.15% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	147.34% Upside
VCEL Vericel	3.00	Buy	$60.33	63.88% Upside

Current Analyst Ratings Breakdown

Latest PRME, VCEL, DYN, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	26.68	N/A	N/A	$10.35 per share	1.62
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
PRME Prime Medicine	$4.96M	97.79	N/A	N/A	$1.37 per share	2.63
VCEL Vericel	$237.22M	7.83	$0.33 per share	113.16	$6.08 per share	6.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	11/4/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
VCEL Vericel	$10.36M	$0.12	306.40	83.67	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest PRME, VCEL, DYN, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.11%	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	6.75	6.75
DYN Dyne Therapeutics	0.17	16.83	16.83
PRME Prime Medicine	N/A	6.50	6.50
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
DYN Dyne Therapeutics	96.68%
PRME Prime Medicine	70.37%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
DYN Dyne Therapeutics	14.14%
PRME Prime Medicine	22.74%
VCEL Vericel	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable
VCEL Vericel	300	50.46 million	47.84 million	Optionable

PRME, VCEL, DYN, and BEAM Headlines

Recent News About These Companies

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCEL

August 20 at 9:12 AM | marketbeat.com

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

August 20 at 4:35 AM | msn.com

11 Best Small-Cap Growth Stocks to Buy Right Now

August 19 at 8:32 AM | insidermonkey.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLC

August 19 at 5:17 AM | marketbeat.com

Public Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Invesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

LPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17, 2025 | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRME, VCEL, DYN, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$16.76 +0.75 (+4.65%)

As of 03:22 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.60 +0.39 (+3.15%)

As of 03:22 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Prime Medicine NYSE:PRME

$3.60 +0.39 (+11.96%)

As of 03:22 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Vericel NASDAQ:VCEL

$36.82 +1.38 (+3.88%)

As of 03:23 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time